- Details
- Sam Chang converses with Matthew Galsky about the ANTICIPATE II trial, examining the combination of APL-1202 (nitroxoline salt) and tislelizumab in treating muscle-invasive bladder cancer. Dr. Galsky discusses APL-1202's journey from an antibiotic with noted anti-cancer properties to a promising cancer treatment due to its immunogenic cell death induction and potential synergy with PD-1 inhibitors...
|
- Details
- Michael Basin presents an analysis on FGFR alterations and the genomic landscape differences between upper and lower tract urothelial carcinoma. Utilizing data from the extensive Foundation Medicine database, which includes around 10,000 bladder cancer patients, Dr. Basin's study focuses on the subset with FGFR mutations. The research reveals that lower tract tumors possess more genomic co-drivers...
|
- Details
- Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with a collaborative team spanning medical oncology to economic experts, has spent over a decade exploring these treatment pathways, revealing significant cost differences and outcomes through extensive research, in...
|
- Details
- Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...
|
- Details
- Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene firadenovec, a novel intravesical gene therapy, highlighting its efficacy and patient-friendly administration schedule. Dr. Tyson shares insights on the drug's mechanism, its clinical trial outcomes, and its o...
|
- Details
- Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...
|
- Details
- Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer. Dr. Canter, drawing from his firsthand experience in Phase 1, 2, and 3 trials, highlights the therapy's tolerability and its efficacy, particularly noting its superior administration schedule compared to BCG. With a focus on real-world application, they explore the si...
|
- Details
- Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials. With nadofaragene firadenovec's unique once-quarterly dosing schedule...
|
- Details
- Ashish Kamat and Professor Sumanta (Monty) Pal discuss the microbiome's influence on genitourinary cancers and immunotherapy. Highlighting foundational research, Dr. Pal explains how the gut microbiome composition affects immunotherapy outcomes, with variability in bacterial species linked to treatment responses. He emphasizes the detrimental impact of antibiotics on immunotherapy efficacy and int...
|
- Details
- Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...
|
